Harold L. Dauerman, M.D.
Professor of Medicine, Cardiovascular Medicine
Department of Medicine
Contact Information
Medical School - Harvard Medical School, Boston, MA
Dr. Dauerman has used both investigator initiated and multi-center registry studies to elucidate optimal interventional cardiology treatment options for high risk patients ,such as those the elderly, women and patients with ST elevation myocardial infarction, and cardiogenic shock.
Dr. Dauerman is currently leading two national trials in interventional cardiology as national principal investigator: the EDUCATE trial will study patients compliance with dual antiplatelet therapy after drug eluting stent placement and determine the optimum duration of antiplatelet therapy. BOSS will randomize patients undergoing cardiac catheterization to different hydration regimens to prevent contrast related kidney injury. Dr. Dauerman is on the steering committee for the international EXCEL trial which will study whether patients with left main coronary disease should be treated with drug eluting stents or coronary artery bypass surgery.
Professor of Medicine
Director, Cardiovascular Catheterization Laboratory
Dauerman HL, Sobel BE. Synergistic treatment of ST segment elevation acute myocardial infarction with pharmacoinvasive recanalization. J Am Coll Cardiol 2003; 42:646-651.
Aggarwal A, Schneider DJ, Sobel BE, Dauerman HL. Temporal differences in inflammation among diabetic patients undergoing coronary stenting. Am J Cardiol 2003; 92:924-929.
Gogo PB, Schneider DJ, Terrien EF, Watkins MW, Sobel BE, Dauerman HL. Relation of leukocytosis to C reactive protein and interleukin 6 among patients undergoing percutaneous coronary intervention. Am J Cardiol 2005; 96:538-542.
Dauerman HL, Yarzebski J, Lessard D, Gore JM, Goldberg RJ. Anemia predicts bleeding, heart failure and death for patients hospitalized with acute myocardial infarction. Am J Cardiol 2005; 96:1379-1383.
Dauerman HL and Sobel BE, Editors. Pharmacoinvasive Therapy for Acute Myocardial Infarction. New York, Taylor Francis, 2005.
Aggarwal A, Schneider DJ, Sobel BE, Dauerman HL. Temporal differences in inflammation among diabetic patients undergoing coronary stenting. Am J Cardiol 2003; 92:924-929.
Dauerman HL, Applegate RJ, Cohen DJ. Vascular closure devices: the second decade. J Am Coll Cardiol 2007;50 1617-1626.
Meyer M, Lewinter MW, Bell S, Dauerman HL. Cardiorenal protective effects of a novel contrast agent. Journal of the American College of Cardiology: Cardiovasular Interventions 2009;2:p 215-221.
Dauerman HL. PCI Pharmacology: From a Triangle to a Square. J Am Coll Cardiology 2008;51: 698-700.
Ahmed BA, Malenka DL, Piper W, Kellet M, Herne M and Dauerman HL. Significantly improved vascular complications among women undergoing PCI: A report from the Northern New England Registry. Circulation: Cardiovascular Intervention 2009; 2: 423-429.
Dauerman HL, Bhatt DB, Smyth SS, French PA, Becker RC. Bridging the gap between clinical trials and applications of antiplatelet therapy for the elderly. American Heart Journal 2010; 159: pp. 508-517.
Becker RC, Scheiman J, Dauerman HL, Spencer F, Rao S, Sabatine M, Johnson DA, Chan F, Abraham NS, Quigley EMM. Management of platelet directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. J Am Coll Cardiol 2009; 54: p 2261-2276.
Dauerman HL. In search of an algorithm to prevent acute kidney injury. J Am Coll Cardiol: Interventions 2009; 2: p. 1125-1127.
Dauerman HL. PCI, diabetes and death. J Am Coll Cardiol 2010;55: p. 1076-1079.
Solomon RJ, Dauerman HL. Contrast Induced Acute Kidney Injury: A Clinician’s Update. Circulation, 2010, in press.
